Company / Capital Expenditures
Viridian Therapeutics, Inc.\DE Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$495.0K
FY2025
5-year range
$338.0K / $898.0K
FY2021-FY2025
Trend
-3.1%
vs FY2024
Sector context
#138 of 194
Health Care
What the data says
At $495,000, Viridian Therapeutics, Inc.\DE's capital expenditures ranks #138 of 194 in the Health Care sector. Capital Expenditures has fluctuated over the past 10 years, ranging from $42,000 in FY2020 to $898,000 in FY2023.
Based on SEC 10-K filings.
$495,000 in FY2025 with a 5-year CAGR of +63.8%.
Declined from $898,000 to $495,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -14.7%
- 5-Year CAGR
- +63.8%
- 10-Year CAGR
- -
Sector benchmark
#138 of 194 in Health CareTop 71% of 194This company $495.0K Sector average $117.5M
▼
-99.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +63.8%, indicating consistent growth.
- In FY2025, capital expenditures decreased 3.1% year-over-year.
- Ranks #138 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $495.0K | -3.1% |
| FY2024 | $511.0K | -43.1% |
| FY2023 | $898.0K | +12.7% |
| FY2022 | $797.0K | +135.8% |
| FY2021 | $338.0K | +704.8% |
| FY2020 | $42.0K | -50.0% |
| FY2019 | $84.0K | -81.1% |
| FY2018 | $445.0K | +80.9% |
| FY2017 | $246.0K | -1.6% |
| FY2016 | $250.0K | +103.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026